S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Is AMC Entertainment Pulling a Fast One on the APEs?
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Sell every Stock except ONE (Ad)
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Saudi Aramco's profits already $88B as oil prices stay high
Sell every Stock except ONE (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Is AMC Entertainment Pulling a Fast One on the APEs?
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Sell every Stock except ONE (Ad)
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Saudi Aramco's profits already $88B as oil prices stay high
Sell every Stock except ONE (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Is AMC Entertainment Pulling a Fast One on the APEs?
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Sell every Stock except ONE (Ad)
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Saudi Aramco's profits already $88B as oil prices stay high
Sell every Stock except ONE (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Is AMC Entertainment Pulling a Fast One on the APEs?
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Sell every Stock except ONE (Ad)
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Saudi Aramco's profits already $88B as oil prices stay high
Sell every Stock except ONE (Ad)
NASDAQ:NVIV

InVivo Therapeutics - NVIV Price Target & Analyst Ratings

$8.11
+0.44 (+5.74%)
(As of 08/12/2022 09:15 PM ET)
Add
Compare
Today's Range
$7.51
$8.20
50-Day Range
$3.75
$8.96
52-Week Range
$3.50
$20.23
Volume
75,400 shs
Average Volume
296,703 shs
Market Capitalization
$11.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

InVivo Therapeutics Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

N/A
Based on 0 Analyst Ratings

Consensus Analyst Price Target

N/A

Get InVivo Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NVIV and its competitors with MarketBeat's FREE daily newsletter.


NVIV Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NVIV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

InVivo Therapeutics Stock vs. The Competition

TypeInVivo TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
0.00
2.70
2.50
Consensus RatingN/ABuyHold
Predicted Upside714.87% Upside13.80% Upside
News Sentiment RatingPositive News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
230
66.47%
Underperform Votes
116
33.53%
Avg. Outperform Votes
165
66.80%
Avg. Underperform Votes
82
33.20%
Avg. Outperform Votes
839
68.71%
Avg. Underperform Votes
382
31.29%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
(Data available from 8/15/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












NVIV Price Target - Frequently Asked Questions

Do MarketBeat users like InVivo Therapeutics more than its competitors?

MarketBeat users like InVivo Therapeutics less than other Medical companies. 66.47% of MarketBeat users gave InVivo Therapeutics an outperform vote while medical companies recieve an average of 66.80% outperform votes by MarketBeat users.


Stock Ratings Reports and Tools

This page (NASDAQ:NVIV) was last updated on 8/15/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.